生血宝合剂联合琥珀酸亚铁片治疗妊娠期缺铁性贫血的疗效及对铁代谢指标和妊娠结局的影响

摘要 目的：探讨妊娠期缺铁性贫血（IDA）患者经生血宝合剂联合琥珀酸亚铁片治疗后，患者疗效、妊娠结局情况以及铁代谢指标变化情况。方法：选择2016年6月~2021年4月期间在我院接受治疗的妊娠期IDA患者100例。根据信封抽签法将患者分为对照组和研究组，各为50例。对照组患者接受琥珀酸亚铁片治疗，研究组患者接受生血宝合剂联合琥珀酸亚铁片治疗，两组患者均治疗1个月。对比两组疗效、红细胞参数、铁代谢指标、妊娠结局和不良反应发生情况。结果：研究组的临床总有效率较对照组明显更高（P>0.05）。治疗1个月后，两组血红细胞计数（RBC）、红细胞平均体积（MCV）、血红蛋白（Hb）、红细胞平均血红蛋白（MCH）均较治疗前升高，且研究组高于对照组（P<0.05）。治疗1个月后，两组血清铁（SI）、转铁蛋白饱和度（TSAT）、铁蛋白（SF）均较治疗前升高，且研究组高于对照组；转铁蛋白受体（STFR）较治疗前降低，且研究组低于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。研究组剖宫产率、低体质量儿出生率低于对照组（P<0.05）。结论：生血宝合剂联合琥珀酸亚铁片治疗妊娠期IDA患者疗效显著，可促进其铁代谢恢复，提高红细胞发育程度，降低剖宫产率及低体质量儿出生率，安全可靠。

Effect of Shengxuebao Mixture Combined with Ferrous Succinate Tablets on Iron Metabolism and Pregnancy Outcome in the Treatment of Iron Deficiency Anemia during Pregnancy

ABSTRACT Objective: To investigate the efficacy, pregnancy outcome and changes of iron metabolism in patients with iron deficiency anemia during pregnancy (IDA) treated with Shengxuebao mixture combined with Ferrous Succinate Tablets. Methods: 100 pregnant IDA patients who were treated in our hospital from June 2016 to April 2021 were selected. According to the envelope lottery method, the patients were divided into control group and study group, with 50 cases in each group. The patients in the control group were treated with Ferrous Succinate Tablets, and the patients in the study group were treated with Shengxuebao mixture combined with Ferrous Succinate Tablets. Both groups were treated for 1 month. The curative effect, erythrocyte parameters, iron metabolism indexes, pregnancy outcome and adverse reactions were compared between the two groups. Results: The total clinical effective rate of the study group was significantly higher than that of the control group(P>0.05). After one month of treatment, the red blood cell count (RBC), mean corpuscular volume (MCV), hemoglobin (Hb) and mean corpuscular hemoglobin (MCH) in the two groups were higher than those before treatment, and the study group was higher than that in the control group(P<0.05). One month after treatment, serum iron (SI), transferrin saturation (TSAT) and ferritin (SF) in the two groups were higher than those before treatment, and the study group was higher than that in the control group; The level of transferrin receptor (STFR) in the study group was lower than that in the control group(P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). The cesarean section rate and birth rate of low body weight infants in the study group were lower than those in the control group(P<0.05). Conclusion: Shengxuebao mixture combined with Ferrous Succinate Tablets is effective in the treatment of IDA patients during pregnancy. It can promote the recovery of iron metabolism, improve the degree of red blood cell development, reduce the rate of cesarean section and the birth rate of low body weight infants. It is safe and reliable.